Article
Engineering, Biomedical
Hao Yang, Heng Li, Fen Yang, Ze Tao, Qiuxiao Shi, Tianshan She, Yanru Feng, Zhao Li, Jie Chen, Yi Zhong, Tao Su, Wengjuan Zeng, Yong Zhang, Shisheng Wang, Lan Li, Tingting Long, Dan Long, Jingqiu Cheng, Hong Zhu, Xiaofeng Lu
Summary: Increasing the valency of death receptor agonist by promoting higher-order receptor clustering is an efficient way to induce tumor cell apoptosis. However, currently available strategies to improve the clustering ability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) often result in large proteins with poor tumor penetration. In this study, we demonstrate that covalent protein ligation using small molecular superglues can assemble higher-order TRAIL variants, leading to significantly increased apoptosis induction in vitro and in vivo.
Article
Biochemistry & Molecular Biology
Raedeh Saraei, Heshu Sulaiman Rahman, Masoud Soleimani, Mohammad Asghari-Jafarabadi, Adel Naimi, Ali Hassanzadeh, Saeed Solali
Summary: The study found that kaempferol can enhance the cytotoxic and pro-apoptotic effects of TRAIL on CML cells by regulating the expression of specific genes, providing a new approach for leukemia therapy.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Oncology
K. M. A. Zinnah, Sang-Youel Park
Summary: The study demonstrated the mechanism behind the synergistic anticancer effect of amitriptyline and TRAIL, showing that amitriptyline increases TRAIL-induced apoptosis by upregulating death receptors DR4 and DR5. Inhibition of autophagy by amitriptyline was also shown to enhance DR4 and DR5 expression.
Article
Multidisciplinary Sciences
Daniel J. Lightwood, Rebecca J. Munro, John Porter, David McMillan, Bruce Carrington, Alison Turner, Anthony Scott-Tucker, Elizabeth S. Hickford, Antje Schmidt, David Fox, Alison Maloney, Tom Ceska, Tim Bourne, James O'Connell, Alastair D. G. Lawson
Summary: TNF can be inhibited by small molecules that stabilize the TNF trimer in an asymmetric conformation. The authors also developed a monoclonal antibody that selectively binds this inactive form of TNF, enabling both target engagement assessment and structural characterization of TNF binding to TNF receptor 1.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Tatsushi Yoshida, Kenta Yamasaki, Kenjiro Tadagaki, Yasumichi Kuwahara, Akifumi Matsumoto, Adem Ejub Sofovic, Noriko Kondo, Toshiyuki Sakai, Tsukasa Okuda
Summary: The study identified RUNX1 as a transcriptional regulator of TRAIL, showing that TRAIL expression is decreased in acute myeloid leukemia patients and inhibited by RUNX1-ETO.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Review
Oncology
Hojjat Alizadeh Zeinabad, Eva Szegezdi
Summary: TRAIL, as a promising anticancer drug with low toxicity, has not been successfully translated into a therapeutic molecule due to its short in vivo half-life and tumor cells' resistance. Nanotechnology shows potential to overcome these limitations and offers better solutions.
Article
Neurosciences
Xiaokun Zhou, Liang Lv, Yuan Tan, Zhongyi Zhang, Shuyang Wei, Shaowen Xiao
Summary: The study demonstrates that Tanshinone IIA enhances TRAIL-induced apoptosis in glioblastoma cells by modulating the expression of STAT3, DR4, and DR5. In vivo experiments show that cotreatment with T-IIA and TRAIL effectively inhibits tumor growth and induces apoptosis in nude mice.
Article
Chemistry, Analytical
Minggang Tian, Baoli Dong, Zheming Zhang, Junling Yin, Weiying Lin
Summary: A new fluorescent probe mPTP-F has been successfully designed to monitor the opening of mPTP in cellular native status. This probe can serve as an important tool for studying areas such as ischemia-reperfusion injury and cell apoptosis.
ANALYTICAL CHEMISTRY
(2022)
Article
Chemistry, Multidisciplinary
Hyeonwoo Je, Gi-Hoon Nam, Gi Beom Kim, Wonjun Kim, Soo Rin Kim, In-San Kim, Eun Jung Lee
Summary: TRAIL shows promising anti-tumor activity, but faces challenges such as resistance and delivery issues. A nanocage has been developed to efficiently deliver TRAIL and a re-sensitizing drug (DOX) to overcome TRAIL-resistant tumors, demonstrating potential as an effective antitumor agent.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Biochemistry & Molecular Biology
Gabriel Ichim, Benjamin Gibert, Sahil Adriouch, Catherine Brenner, Nathalie Davoust, Solange Desagher, David Devos, Svetlana Dokudovskaya, Laurence Dubrez, Jerome Estaquier, Germain Gillet, Isabelle Guenal, Philippe P. Juin, Guido Kroemer, Patrick Legembre, Romain Levayer, Stephen Manon, Patrick Mehlen, Olivier Meurette, Olivier Micheau, Bernar Mignotte, Florence Nguyen-Khac, Nikolay Popgeorgiev, Jean-Lu Poyet, Muriel Priault, Jean-Ehrlan Ricci, Franck B. Riquet, Santos A. Susin, Magal Suzanne, Pierre Vacher, Ludivine Walter, Bertran Mollereau
Summary: Since the Nobel Prize was awarded more than twenty years ago for discovering the core apoptotic pathway in C. elegans, researchers around the world have conducted extensive research on apoptosis and various other forms of regulated cell death. Although there are still many aspects of regulated cell death that need to be clarified in specific cell subtypes and disease conditions, the last decade has seen the description of multiple cell death modalities, some of which have been successfully used in clinical therapy. To keep research into cell death alive, francophone researchers from several institutions in France and Belgium established the French Cell Death Research Network (FCDRN), which is at the forefront of emerging topics in cell death research. These research efforts will enhance our mechanistic knowledge of regulated cell death and its therapeutic applications in the coming years.
Article
Chemistry, Multidisciplinary
Tianshan She, Fen Yang, Shiyuan Chen, Hao Yang, Ze Tao, Huimin Xing, Jie Chen, Huansheng Chang, Hongyu Lu, Tao Su, Youmei Jin, Yi Zhong, Jingqiu Cheng, Hong Zhu, Xiaofeng Lu
Summary: The clinical application of TRAIL is limited by its inefficient induction of apoptosis in tumor cells. Superglue-mediated hyperoligomerization of TRAIL can increase its valency and improve its efficacy. In this study, minimal superglue peptide pairs were fused to the TRAIL promoter to create superglue-fusion TRAIL variants. These variants showed high expression and trimerization similar to native TRAIL. With the help of Snoopligase or SpyStapler, these variants could be crosslinked into hexavalent TRAIL variants. The hexavalent SnHexaTR variant produced by Snoopligase showed the highest yield and exhibited 10-40 times greater cytotoxicity than native TRAIL in tumor cells. It also had a longer half-life and greater tumor uptake, leading to the eradication of tumor xenografts. Hexavalent SnHexaTR, as a novel anticancer agent candidate, has great potential for clinical application in cancer therapy.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Min Huang, Cheng Yi, Xian-Zhou Huang, Juan Yan, Li-Jia Wei, Wei-Ju Tang, Shou-Chun Chen, Ying Huang
Summary: TRAIL-Mu3 exhibits stronger antitumor effects on pancreatic cancer cells compared with TRAIL by enhancing the apoptotic signaling pathway.
Article
Medicine, Research & Experimental
Wen-juan Jiang, Chuan-ting Xu, Chang-lin Du, Jia-hui Dong, Song-bing Xu, Bing-feng Hu, Rui Feng, Dan-dan Zang, Xiao-ming Meng, Cheng Huang, Jun Li, Tao-tao Ma
Summary: This study revealed a novel cell communication mechanism between tubular epithelial cells and macrophages in diabetic nephropathy. The communication is mediated by extracellular vesicles enriched with LRG1 and TRAIL, leading to worsened kidney damage and activation of inflammation.
Article
Immunology
Wenhao Xu, Hai-Jia Tang, Aihetaimujiang Anwaier, Wangrui Liu, Xi Tian, Jiaqi Su, Shiyin Wei, Yuanyuan Qu, Hailiang Zhang, Dingwei Ye
Summary: This study evaluated the transcriptomic profile of cell death pathways in bladder cancer patients and found that patients with high cell-death index (CDI) had a higher risk of mortality. These high-risk patients also exhibited an immunoevasive tumor microenvironment characterized by increased tumor-associated macrophage infiltration and expression of immune checkpoints. These findings provide important clinical and immunological insights for the management of bladder cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Olivia A. Diaz Arguello, Hidde J. Haisma
Summary: Cancer, a complex disease marked by evasion of apoptosis, can potentially be treated by inducing apoptosis in cancerous cells. Among the tumor necrosis factor (TNF) protein family, certain ligands possess apoptosis-inducing capabilities. Various recombinant TNF apoptosis-inducing ligands have been developed over time to improve their effectiveness in cancer treatment.
Article
Dermatology
Matthew J. Davis, Gokul Srinivasan, Rachael Chacko, Sophie Chen, Anish Suvarna, Louis J. Vaickus, Veronica C. Torres, Sassan Hodge, Eunice Y. Chen, Sarah Preum, Kimberley S. Samkoe, Brock C. Christensen, Matthew R. Leboeuf, Joshua J. Levy
Summary: The development and application of AI algorithms are of great significance for the removal of cSCC, as they can improve operational efficiency and accuracy, especially for moderately and poorly differentiated tumors/ neoplasms. Further improvement is needed to maintain sensitivity to surrounding tissue and determine anatomical positioning.
EXPERIMENTAL DERMATOLOGY
(2024)
Article
Dermatology
Lingjing Chen, Qing Yu, Feiying Guo, Xuewen Wang, Zhenying Cai, Qiang Zhou
Summary: This study investigated the role and mechanisms of NTS in stress-induced hair growth inhibition. The results demonstrated that NTS effectively counteracted hair growth inhibition caused by stress and regulated the expression of multiple genes related to hair growth at the transcriptional level.
EXPERIMENTAL DERMATOLOGY
(2024)
